Trial · NCT00289211
Results by group36
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 36
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Time to Beginning of Substantial Relief of the Defining Symptom | C1INH-nf | 2.0 | 95% Confidence Interval 1.0 to 4.0 | hours | |
| Time to Beginning of Substantial Relief of the Defining Symptom | Placebo | 4.0 | 95% Confidence Interval 2.0 to 4.0 | hours | |
| Number of Subjects With Beginning of Substantial Relief of the Defining Symptom | C1INH-nf | 21 | participants | ||
| Number of Subjects With Beginning of Substantial Relief of the Defining Symptom | Placebo | 14 | participants | ||
| Time to Complete Resolution of the HAE Attack | C1INH-nf | 12.3 | 95% Confidence Interval 10.1 to 18.0 | hours | |
| Time to Complete Resolution of the HAE Attack | Placebo | 31.6 | 95% Confidence Interval 17.8 to 46.0 | hours | |
| Antigenic C1 Inhibitor (C1INH) Serum Levels | C1INH-nf | Pre-infusion (N=34, N=33) | 14.7 | Standard Deviation 22.21 | mg/dL |
| Antigenic C1 Inhibitor (C1INH) Serum Levels | Placebo | Pre-infusion (N=34, N=33) | 13.0 | Standard Deviation 16.42 | mg/dL |
| Antigenic C1 Inhibitor (C1INH) Serum Levels | C1INH-nf | Change at 1 hour post-infusion (N=35, N=32) | 6.7 | Standard Deviation 8.86 | mg/dL |
| Antigenic C1 Inhibitor (C1INH) Serum Levels | Placebo | Change at 1 hour post-infusion (N=35, N=32) | -0.9 | Standard Deviation 9.25 | mg/dL |
| Antigenic C1 Inhibitor (C1INH) Serum Levels | C1INH-nf | Change at 2 hours post-infusion (N=23, N=27) | 11.7 | Standard Deviation 12.86 | mg/dL |
| Antigenic C1 Inhibitor (C1INH) Serum Levels | Placebo | Change at 2 hours post-infusion (N=23, N=27) | 0.5 | Standard Deviation 6.73 | mg/dL |
| Antigenic C1 Inhibitor (C1INH) Serum Levels | C1INH-nf | Change at 4 hours post-infusion (N=28, N=23) | 8.6 | Standard Deviation 8.92 | mg/dL |
| Antigenic C1 Inhibitor (C1INH) Serum Levels | Placebo | Change at 4 hours post-infusion (N=28, N=23) | 0.4 | Standard Deviation 6.72 | mg/dL |
| Antigenic C1 Inhibitor (C1INH) Serum Levels | C1INH-nf | Change at 12 hours post-infusion (N=19, N=13) | 5.6 | Standard Deviation 11.21 | mg/dL |
| Antigenic C1 Inhibitor (C1INH) Serum Levels | Placebo | Change at 12 hours post-infusion (N=19, N=13) | -0.8 | Standard Deviation 4.39 | mg/dL |
| Functional C1INH Serum Levels | C1INH-nf | Pre-infusion (N=34, N=31) | 35.6 | Standard Deviation 22.62 | percent of functional C1INH |
| Functional C1INH Serum Levels | Placebo | Pre-infusion (N=34, N=31) | 33.7 | Standard Deviation 29.04 | percent of functional C1INH |
| Functional C1INH Serum Levels | C1INH-nf | Percent change 1 hour post-infusion (N=35, N=32) | 31.5 | Standard Deviation 23.94 | percent of functional C1INH |
| Functional C1INH Serum Levels | Placebo | Percent change 1 hour post-infusion (N=35, N=32) | -6.4 | Standard Deviation 23.73 | percent of functional C1INH |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00289211/results